NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Obinutuzumab

Last Revision: December 3, 2018.

Estimated reading time: 1 minute

CASRN: 949142-50-1

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of obinutuzumab during breastfeeding. Because obinutuzumab is a large protein molecule with a molecular weight of about 150,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, obinutuzumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.[1] The manufacturer recommends that breastfeeding be discontinued during obinutuzumab therapy.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.
Pistilli B, Bellettini G, Giovannetti E et al. Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: How should we counsel cancer patients about breastfeeding? Cancer Treat Rev. 2013;39:207-11. [PubMed: 23199900]

Substance Identification

Substance Name

Obinutuzumab

CAS Registry Number

949142-50-1

Drug Class

  • Breast Feeding
  • Antibodies, Monoclonal
  • Antineoplastic Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Related information

Similar articles in PubMed

  • Review Nivolumab[Drugs and Lactation Database (...]
    Review Nivolumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Dinutuximab[Drugs and Lactation Database (...]
    Review Dinutuximab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Pertuzumab[Drugs and Lactation Database (...]
    Review Pertuzumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Cetuximab[Drugs and Lactation Database (...]
    Review Cetuximab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Pembrolizumab[Drugs and Lactation Database (...]
    Review Pembrolizumab
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...